Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
AstraZeneca
Merck
Dow
Moodys

Last Updated: March 26, 2023

Details for Patent: 7,115,587


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 7,115,587 protect, and when does it expire?

Patent 7,115,587 protects ABILIFY and is included in one NDA.

Protection for ABILIFY has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-one patent family members in thirty-one countries.

Summary for Patent: 7,115,587
Title:Aripiprazole complex formulation and method
Abstract:An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a .beta.-cyclodextrin, preferably, sulfobutyl ether .beta.-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.
Inventor(s): Nerurkar; Manoj (Monmouth Junction, NJ), Naringrekar; Vijay (Paramus, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:10/642,366
Patent Claim Types:
see list of patent claims
Formulation; Use;

Drugs Protected by US Patent 7,115,587

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Otsuka ABILIFY aripiprazole INJECTABLE;INTRAMUSCULAR 021866-001 Sep 20, 2006 DISCN No No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,115,587

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 040887 See Plans and Pricing
Argentina 102101 See Plans and Pricing
Austria 428423 See Plans and Pricing
Australia 2003269965 See Plans and Pricing
Brazil 0313602 See Plans and Pricing
Canada 2495864 See Plans and Pricing
China 100335047 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
AstraZeneca
Merck
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.